马上注册登录，享用更多感控资源，助你轻松入门。
您需要 登录 才可以下载或查看，没有账号？注册
|
×
Volume 9, Issue 3, March 2009, Pages 153-161
Review Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
多耐药TB患者治疗预后：系统回顾和meta分析
Evan W Orenstein BSa, b, , , Sanjay Basu PhDa, b, c, N Sarita Shah MDa, d, Jason R Andrews MDa, e, Gerald H Friedland MDa, b, c, Anthony P Moll MBChBa, f, Neel R Gandhi MDa, d and Alison P Galvani PhDa, b
aTugela Ferry Care and Research Collaboration, Tugela Ferry, KwaZulu-Natal, South Africa
bDepartment of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
cAIDS Program, Yale University School of Medicine, New Haven, CT, USA
dDivisions of General Internal Medicine, Infectious Diseases, and Epidemiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
eDepartment of Internal Medicine, University of California San Francisco, San Francisco, CA, USA
fChurch of Scotland Hospital and Philanjalo, Tugela Ferry
Available online 23 February 2009.
SummaryMultidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a Bayesian random-effects meta-analysis of the available therapeutic studies to assess how the reported proportion of patients treated successfully is influenced by differences in treatment regimen design, study methodology, and patient population. Successful treatment outcome was defined as cure or treatment completion. 34 clinical reports with a mean of 250 patients per report met the inclusion criteria. Our analysis shows that the proportion of patients treated successfully improved when treatment duration was at least 18 months, and if patients received directly observed therapy throughout treatment. Studies that combined both factors had significantly higher pooled success proportions (69%, 95% credible interval [CI] 64–73%) than other studies of treatment outcomes (58%, 95% CI 52–64%). Individualised treatment regimens had higher treatment success (64%, 95% CI 59–68%) than standardised regimens (54%, 95% CI 43–68%), although the difference was not significant. Treatment approaches and study methodologies were heterogeneous across studies. Many important variables, including patients' HIV status, were inconsistently reported between studies. These results underscore the importance of strong patient support and treatment follow-up systems to develop successful MDR tuberculosis treatment programmes. |
发表于 2009-2-27 15:28
发表于 2009-2-27 16:16